CAR T-Cell Data in Multiple Myeloma

ASH 2019 – Multiple Myeloma
Videos
Leslie Lauersdorf, ARNP
Moffitt Cancer Center
Tampa Bay, FL
Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma.

Related Items

LCAR-B38M CAR-T Therapy Yields High Complete Response Rate and Survival Time
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
GRIFFIN Study: Daratumumab Deepens Responses Over Time
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Benefit Shown for Daratumumab plus Carfilzomib + Dexamethasone
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Study Moves CAR-T Therapy Forward in Myeloma
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
What is Minimal Residual Disease (MRD) Negativity?
By Leslie Lauersdorf, ARNP
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
In Routine Practice, Ixazomib Regimen Mirrors Efficacy of Clinical Trial
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
Multiple Myeloma as a Chronic Disease
By Leslie Lauersdorf, ARNP
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma

© Amplity Health. All Rights Reserved. Privacy Policy